Transcript Diapositive 1

CEDHYS Business tour in ISRAËL
5th to 11th November 2012
CEDHYS Business tour in Israël
1
Table of contents

Attendees presentation
CEDHYS Business tour in Israël
2
BIOGARAN: Antoine JUMELLE

June 2010 – Present (2 years 3 months): CIO of BIOGARAN Biogaran is the second Pharmaceutical Generic's
Laboratory in France.

2001 – June 2010 (9 years) IT Division Manager at Servier Privately Held; 10,001+ employees;
Pharmaceuticals industry
+ IT Quality Manager
+ IT Security Survey Manager
+ International IT Coordination (140 countries)
+ Project Leader SAP Finance for the main French affiliate

1996 – 2001 (5 years): IT Department Manager at Servier
Technical & Support Department (2500 users)
- Workstations Policy (Harware-Software-Contract Negociations)
- Supports (2500 users - 25 000 calls / year)
- Networks LAN/CAN
- Movings
French Laboratory, Biogaran markets more than 530 generic medications. His philosophy is to produce all
genericable molecules, the blockbuster drug and more confidential. Whatever the origin of the laboratory
"princeps" (parent drug).
Results: a range that can treat more than 80 diseases.
Biogaran goes further: the laboratory since its inception has become an ethical approach that recognizes the
limits of medicine. For Biogaran drugs are active substances to be used properly. His commitment is backed by
concrete actions towards a better use of medicines and better monitoring of treatment (compliance) by the
patient. Biogaran invests a portion of its profits in this process through the establishment of free services (or
cost):
Tools secure daily use of the drug (creation of packages which facilitate the transmission of treatment doctor,
pharmacist and patient, clear and legible notices)
Services to reduce certain risk behaviors among young women (creating a mobile cover to reduce opportunities
to forget his regular contraception)
Services to reduce certain risk behaviors among children (creation of the case Médikid to promote safer
treatments transmission between nearby)
Services to facilitate the practice of medication at home.
CEDHYS Business tour in Israël
3
BOUCHARA-RECORDATI: Jean VINCENEUX


Since 2005: BOUCHARA RECORDATI (400 employees)
IT MANAGER – FRANCE Laboratoires BOUCHARA RECORDATI is a subsidiary of RECORDATI group,
located in Milan.
I have the responsibility of IT department for all sites in France, including the
administrative offices (Levallois-Perret), the factories (St-Victor and Nanterre) and
ORPHAN Europe Company (Paris – La Défense). I report directly to RECORDATI CIO
From 2004 to 2005: BOUCHARA RECORDATI (400 employees)
IT Project manager
I was responsible for implementation of different IT projects especially for SAP
software, sales and distribution modules
Recordati, established in 1926, is a European pharmaceutical group, listed on the
Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271),
with a total staff of over 3,200, dedicated to the research, development,
manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy,
operations in the main European countries, in Central and Eastern Europe and in
Turkey. A field force of around 1,700 medical representatives promotes a wide range
of innovative pharmaceuticals, both proprietary and under license, in a number of
therapeutic areas including a specialized business dedicated to treatments for rare
diseases. Recordati is a partner of choice for new product licenses from companies
which do not have a European presence. Recordati is committed to the research
and development of new drug entities within the cardiovascular and urogenital
therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2011
was € 762.0 million, operating income was € 163.5 million and net income was €
116.4 million.
CEDHYS Business tour in Israël
4
CEVA: François TRICOT

Chief Information Officer at CEVA Santé Animale

Over 15 years of multicultural experience in the IT industry, in various management positions (Skill Centre
Manager, Cief Information Officer)
April 2008 - Present (4 years 5 months):

- Transform group IT to match the challenges of today and tomorrow
- Foster organisation and structure


February 2006 - March 2008 (2 years 2 months): Manager at Aspire
Aspire is the largest Capgemini outsourcing services project with more than 5000 staff delivering IT solutions to
HMRC, the UK tax agency
- Implemented productivity improvements in the Test discipline (a 400 people skill centre),
- Industrialised delivery practices for productivity improvements - Accelerated Delivery Centre (a 200 people
business unit),
- Defined architecture principles of a massively scalable architecture for the HMRC internet portal (several
million users, peak usage for Self-Assessment) (a 100 people project)
Ceva Santé Animale is one of the Top 10 veterinary health company. Ceva's expertise centres are on the two
fields of pharmacology and biology, and has dedicated teams that aim to meet the specific demands of the
companion animal, poultry, ruminant and swine sectors. Ceva's operation are all around the globe in 42 countries,
with 21 factories and 13 R&D centers. About 3000 people work at Ceva and the fast growing turnover is above
500 M€.
CEDHYS Business tour in Israël
5
DANONE Research: Laurent ANTIBI



Information Systems Director Danone Group
February 2007 – Present (5 years 8 months)
Information Systems Director in charge of R&D function and Research Centers
June 2003 – January 2007 (3 years 8 months) Danone Group Head Quarters
Project Director in charge of CRM and Web Solutions
September 2000 – May 2003 (2 years 9 months) Danone headquarters
CRM IS Manager : Multichanel Marketing Campain Management - consumer database
Danone Group, a french company , world leader in food industry
101 000 people / 19,3 b€ turn over
4 divisions : Dairy, Waters, Baby Food, Medical Nutrition
Nutrition for Health is at the heart of Danone ‘s Strategy
CEDHYS Business tour in Israël
6
Flamel Technologies: Raphaël COMMARET


Information Technology Manager, since 2003
Flamel Technologies R&D, Pharmaceutical Industry (~250 employees)
Also in charge of the compliance of IT systems with FDA regulation and Sarbanes-Oxley act.
2000-2003: Accenture Consulting & technology services company: IT consultant
Flamel Technologies SA (NASDAQ: FLML) is a leading drug delivery company focused on the goal
of developing safer, more efficacious formulations of drugs to tackle unmet medical needs.
Our product development pipeline includes biological and chemical drugs formulated with our
proprietary platforms :
- Medusa platform (injectable drugs) allows formulation and/or extended release of biologics
(including proteins, antibodies and peptides) and also small molecules.
Several Medusa-based products are at various clinical stages of development; Medusa’s lead
internal product candidate IFN-a XL is currently the subject of a Phase 2 trial in HCV patients.
DeliVax®, Medusa’s vaccine application, permits the efficient formulation of vaccines.
- Micropump platform (oral drugs) allows formulation and controlled release of chemical drugs
that are best absorbed in the small intestine.
- LiquiTime® allows extended release liquid formulations of drugs for patients who have difficulty
swallowing tablets or capsules, particularly children and the elderly.
- Trigger Lock™ allows tamper-resistant controlled release formulations of narcotics and other
drugs susceptible to abuse.
CEDHYS Business tour in Israël
7
GALDERMA: Thierry BARSALOU
Dr. Thierry Barsalou is Chief Information Officer for Galderma, a fully integrated pharmaceutical
company exclusively focused on dermatology. As CIO, Thierry has global responsibility over
Information Technology throughout the company. Thierry brings 30 years of experience in
the technology and healthcare industries alternating between successful start-ups and varied
positions of increasing responsibility at large companies such as IBM, Novartis and Ipsen. He
has lived and worked in France, the US, Switzerland, Canada and Belgium. Thierry holds an
MD degree from University of Paris, France, and a PhD in Medical Information Sciences from
Stanford University.
Galderma is a global pharmaceutical company founded in 1981 and exclusively focused on
dermatology. The company has 31 wholly-owned affiliates and 4,000 employees. Galderma’s
extensive product portfolio treats a range of dermatological conditions including: acne, rosacea,
onychomycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancer
and medical solutions for skin senescence. In 2011, Galderma acquired Q-Med, a Swedish
medical device company specialized in aesthetics, strengthening Galderma’s presence in the
aesthetic and corrective market. With approximately 19% of revenues invested each year to
discover and develop new products and access innovative technologies, the company is one of
the world’s leading investors in dermatology R&D.
CEDHYS Business tour in Israël
8
LFB: Jean-Louis QUEVA

2004 – Present (8 years): CIO at LFB

2001 – 2003 (3 years): Hypermarket CIO at CARREFOUR

1996 – 2001 (5 years): International Project Manager at AIR LIQUIDE
LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the
treatment of serious and often rare diseases in major therapeutic areas: immunology, haemostasis, and
intensive care.
LFB group is the leading manufacturer of plasma-derived medicinal products in France and the 6th largest
player worldwide. It is also among the leading European companies in the development of monoclonal
antibodies and new-generation proteins based on biotechnologies.
With its strong research activities, LFB group is developing a growth strategy to expand its business
activities by offering new therapeutic treatments and expanding into new international markets.
CEDHYS Business tour in Israël
9
NUTRICIA: France GENNEQUIN

Since Feb.2009 : IS Director of NUTRICIA

2001 – 2008 : DANONE GROUP :
o 2004 – 2008 : IT Operations Project Manager + Application Administration Manager
In charge of the projects for all IT Operations of Danone – 33 customer companies, 8000 users, worldwide
implementation. Coordination of 120 IT People.
o 2003 : IS Deployment Manager : Dannon US & Danone Canada
In charge of the deployment of SAP in Danone Canada and The Dannon Company, Inc.
o 2001 – 2002 : Development Manager of Danone Group
In charge of realizing all R/3 developments for the Core SAP System of Danone and for the 1s deployment wave

2000 : Deployment Project Manager at SODEXHO acting as Director of the SAP Competency Center

1999 : SAP Consultant at CMG

1997 : Study & Development Engineer at AXA
Nutricia Nutrition Clinique SAS is the French business unit of « Medical Nutrition »
division of Danone Group. Our products are intended for the nutritional management
of diseases and medical conditions (malnourished adults, metabolic disorder,
complete nutrition for patients who cannot meet their nutritional needs orally, etc.).
They are used under the direction of Healthcare professionals.
Nutricia Nutrition Clinique sells & distributes nutrition products via several distribution
canals (Pharmacies, Hospitals, Wholesalers, Homecare professionals) in France and
export (DOM-POM, Maghreb). It is a business unit of 180 employees (half sales
force, half HQ) for a 2011 CA of 107 M€
CEDHYS Business tour in Israël
10
STAGO: Jean-Marc OBENICHE

Since 2010 : STAGO, DIRECTOR IT – in charge of innovations and management control.

1993 – 2010 : STAGO, C.I.O.

1989 – 1993 : FROMAGERIES BEL – Cheese maker company (Laughing cow, Babybel..), Development
Manager

1985 – 1989 : Laboratoires JANSSEN- (JOHNSON & JOHNSON affiliate) Office automation and Lan
Manager
Stago is a pharmaceutical laboratory, founded in 1945, which now operates in the
In vitro Diagnosis (IVD) industry, wholly dedicated to the exploration of haemostasis
and thrombosis. (Reagents and devices)
CEDHYS Business tour in Israël
11
STALLERGENES: Thierry GREHAIGNE

from 1996 till today
STALLERGENES S.A., Pharmaceutical lab, Worldwide leader in immunotherapy
(desensitization to allergies). 250M€ of revenues, 40% out of France. 1.000 employees.
Vice-President Information Technologies
 Staff : 35 people, annual OPEX : 3,5 M€, annual CAPEX : 4,5 M€
 Building of a new Corporate Information System (based on M3, ERP from LAWSON/INFOR
Company) with deployment throughout Headquarters and affiliates
 Implementation of E.DI. flows with third-party companies, for payment of the delivered products
to patients (more than 3.000 deliveries per day)
 Due diligence coordination before acquisition of a competitor
 Implementation of a new Company organization for management of transformation and product
development projects.

From1994 to 1996
CORNING FRANCE, Scientific & ophthalmic glass manufacturer, affiliate of
CORNING Inc., worldwide leader in technical glass and optical fiber. 450 MF of turnover, 70% out of France. 600
employees.
Supply chain & IT Director
Stallergenes is a European biopharmaceutical company dedicated to the treatment of allergy-related
respiratory diseases, such as severe rhinoconjunctivitis and rhinitis, as well as allergic asthma, using
allergen immunotherapy. The leader in sublingual immunotherapy treatment, Stallergenes devotes
almost 20% of its gross sales to Research & Development and is actively involved in the development
of a new therapeutic class: sublingual immunotherapy tablets.
In 2011, the company had sales of € 235 million, and more than 500,000 patients were treated with
Stallergenes products.
CEDHYS Business tour in Israël
12
URGO: Patrice CAULFUTY

January 2003 – Present (8 years 9 months): Chief Information Officer (CIO) of Laboratoires Urgo
Privately Held; 1300 employees; Pharmaceuticals industry (manufacture solutions to treat common ailments and
high-tech healing products)
Define the IT strategy and policy (ERP SAP, Development, Lan, Wan, Labtop, web …)
Management of the IT Department (20 people)
International IT Coordination (15 affiliates)
IT Quality Manager (FDA compliance)
Responsible for SAP Roll out projects in Europe and Asia (5 countries)
Roll out CRM SalesForce and CLM (Skura) software in Asia

1998 – 2002 (4 years): IT Department Manager at Laboratoires Fournier Privately Held; 4000+ employees;
Pharmaceuticals industry
SAP skill Department manager (10 people)
Support and maintenance in SAP (upgrade, customizing …)
IT Security Manager
Roll out SAP in 5 countries
Laboratoires Urgo’s Healthcare Division focuses its
expertise on reference brands: Urgo, the top foot, hand
and wound care brand is extending its leadership to
mouth wounds with Urgo Mouth Ulcers and Cold Sores.
Humex, No. 1 in the upper respiratory tract infection
market, is strongly positioned in the cold and allergy
segments with, in particular, its hay fever treatment
containing Beclomethasone. A historic player in these
markets, Urgo Healthcare expanded its expertise to
create a third major section dedicated to
vitamin supplements in 2004. The launch of ImmunoStim
in 2006 and the acquisition of Alvityl in 2008 have
enabled it to further strengthen its position and become a
key player in the child and family health segment.
Urgo Healthcare makes the health URGO & HUMEX
of these “consum-actors” its central focus, offering
them safe, effective and innovative products.
Voted most innovative OTC company in pharmacies in
2009, Urgo Healthcare is continuing to grow thanks to its
drive for innovation and expertise, enabling it to offer its
customers advanced, high-tech solutions.
URGO MEDICAL,
a reference for health professionals
Urgo Medical, a wound-healing expert, is committed to working
with health professionals day after day to advance knowledge in
the field of wounds and develop innovative treatments designed
to improve patients’ quality of life and help them heal more quickly.
Today, Urgo Medical offers high-tech solutions for the treatment
of serious and incapacitating conditions: burns, pressure sores, leg
ulcers, epidermolysis bullosa, diabetic foot ulcers. Urgo Medical’s
teams strive on a daily basis to meet their commitment to relieve pain,
simplify treatments and make life easier for patients.
In 2000, Urgo Medical revolutionised the wound healing
market by inventing Technology Lipido-Colloid (TLC) – leading to the
development of Urgotul® – establishing itself as the gold standard
in the management of acute wounds.
Using “Pressure System” technology developed as a result of
Urgo Research, Urgo Medical created the first compression system with
two active bandages in 2008: UrgoK2. In 2011, a new technological and
scientific advance with UrgoStart*, a healing accelerator treatment.
CEDHYS Business tour in Israël
13
VETOQUINOL: Pierre-Yves COLIN


12/06- now : VETOQUINOL (Lure) – Group Director, Information System Member of Group Steering
Committee
Definition and implementation of IT strategy of Vetoquinol Group. Management of IT team (40 people). Annual
budget 6,5 M€ over 24 affiliates.
Creation and structuration of Group IT Department, JDEdwards ERP Programm roll out in Spain, Poland, India,
USA. Implementation of LIMS, Group CRM, Business Intelligence.
Direct management of IT of several affiliates : USA, Canada and India.
01/03- 12/06 : GROSFILLEX (Oyonnax) – Organization and Information System Director
Definition and implementation of the IT Strategy of Grosfillex. Management of IT teams (20people). Direct
management of USA and Russia’s IT.
Business process redesign projects : French logistic reorganization (charter, transport planification and
purchases), audit of material flows (semi-finished) within “Window” division then implementation of tracability,
monitoring procedures and dashboards. Implementation of new logistic standards regarding transportation
costs.
North America : Audit and improvement (sales forecasts, production planification, supply).
Implementation of MOVEX ERP.
Russia : Active participation to the creation of the russian affiliate (backoffice, industrial andlogistics) Implementation of 1C local ERP.
The 10th largest veterinary pharmaceutical company in the world and the 3rd largest dedicated to animal health,
Vétoquinol is first and foremost an independent, family-owned business. Deeply committed to its values, it has always
enjoyed a close relationship with its vet clients.
Vétoquinol’s growth and development strategy focuses on innovation and finding the right balance between two major
markets: companion animals and livestock, bred for human food.
Historically based in France,Vétoquinol currently develops, produces and distributes a wide range
of more than 700 medical and non-medical products in Europe,Americas and Asia-Pacific.With
a presence in 23 countries through its subsidiaries, its strong network of 140 distributor partners
provides visibility for its products in more than 100 countries.
CEDHYS Business tour in Israël
14
VIRBAC: Patrick LALOUETTE

Since 02/2002 : CIO of VIRBAC SA (French Group) with 3500 p (35 subsidiaries / 8 plants worldwide)
PHARMACY – Animal Health

2001-2002: CIO of LVMH Fashion Group Division 4Mds Eu (13 brands & 220p in IT .) LUXURY AND LEATHER
GOODS (Vuitton, Kenzo, Celine, Givenchy, Lacroix, etc. ..) (Distribution - Retail with 980 stores)

1998-2001 CIO division of VIVENDI UNIVERSAL PUBLISHING 1100 p 1 billion (+100p. in IT) SERVICES
Founded in 1968 in Carros, near Nice, Virbac is dedicated exclusively to animal health. With a turnover of
623 million euros in 2011, the company now occupies 8th veterinarian pharmaceutical group worldwide.
Its wide range of vaccines and medicines used to prevent and treat major diseases of pets and livestock.
CEDHYS Business tour in Israël
15